NCT07675980 Thymosin-α1 for Recurrent Implantation Failure
| NCT ID | NCT07675980 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | Fakih IVF Fertility Center |
| Condition | Recurrent Implantation Faliure |
| Study Type | INTERVENTIONAL |
| Enrollment | 136 participants |
| Start Date | 2026-02-11 |
| Primary Completion | 2027-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 136 participants in total. It began in 2026-02-11 with a primary completion date of 2027-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Clinical trial evaluating the safety and efficacy of Thymosin-α1 (Tα1) as an adjunctive immunomodulatory therapy in women with unexplained recurrent implantation failure (RIF) undergoing IVF/ICSI cycles.
Eligibility Criteria
Inclusion Criteria: 1. -Women 18-40 years 2. -RIF- ≥2 failed embryo transfers with PGT-a tested euploid embryos 3. \- Normal parental karyotypes 4. \- Normal uterine cavity on imaging 5. \- Negative antiphospholipid panel 6. \- Thyroid and prolactin controlled within local reference standards Exclusion Criteria: 1. Identified/correctable non-immune cause of RPL (chromosomal, anatomic, endocrine) 2. \- Active malignancy 3. -Active infection 4. \- Uncontrolled systemic disease 5. \- Current systemic immunosuppression
Contact & Investigator
Dr. Michael Fakih, MD
PRINCIPAL INVESTIGATOR
Fakih IVF Abu Dhabi
Frequently Asked Questions
Who can join the NCT07675980 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 40 Years, studying Recurrent Implantation Faliure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07675980 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07675980 currently recruiting?
Yes, NCT07675980 is actively recruiting participants. Contact the research team at lamiya.mohiyiddeen@fakihivf.com for enrollment information.
Where is the NCT07675980 trial being conducted?
This trial is being conducted at Abu Dhabi, United Arab Emirates, Abu Dhabi, United Arab Emirates.
Who is sponsoring the NCT07675980 clinical trial?
NCT07675980 is sponsored by Fakih IVF Fertility Center. The principal investigator is Dr. Michael Fakih, MD at Fakih IVF Abu Dhabi. The trial plans to enroll 136 participants.